PIPELINE
ANTICIPATED TIMELINE FOR TELOMIR-1
2026Q2
Toxicology: Completion of formal toxicology
Regulatory: Prepare IB (Investigational New Drug Application). IND submission
Clinical: Formal toxicology
2026Q3
Regulatory: Initiation of Phase I/II studies
2026Q4
Regulatory : Ongoing Phase I/II studies
2026Q4
Regulatory: Ongoing Phase I/II studies
market opportunity
Summary of US Epidemiology
The eligible patient pool analysis for Telomir-1 highlights a potential large patient pool looking for potential treatments to their conditions.
| Total Eligible Population | Diagnosed Prevalence | Treatment Rate | Total Addressable Market | |
| Type 2 Diabetes | 34-45M | 25-27M | 88% | $57.47B |
| Cancer | 18M | 1.9M | Nearly 100% | $16.7B |
| Alzheimer’s Disease | 6.5M | 6.5M | 50% | $3.1B |
| AMD | 19.8M | 20M | Variable. Around 20% | $18B |
market opportunity for rare diseases
| Total Eligible Population | Diagnosed Prevalence | Treatment Rate | Total Addressable Market | |
| Progeria (Hutchinson-Gilford Progeria Syndrome) | 20 children in the U.S. | Most cases | Limited, Lonafarnib is the only approved drug | Minimal |
| Wilson’s Disease | 6-10K | Many cases remain undiagnosed. | Includes chelating agents like penicillamine and zinc salts. | $200-900M |
| Friedreich’s Ataxia | 6K | Most cases | SKYCLARYSTM (omaveloxolone) is the first FDA-approved treatment. | $600.5M, projected to reach 1.71B by 2034 |
| Menkes | 16-40 new cases annually | Improved detection through genetic testing | Includes parenteral copper histidinate administration. | Limited |
Growth Strategy
